These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 23062985)

  • 1. Drug discovery for diabetic nephropathy: trying the leap from mouse to man.
    Breyer MD
    Semin Nephrol; 2012 Sep; 32(5):445-51. PubMed ID: 23062985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diabetic kidney disease in the db/db mouse.
    Sharma K; McCue P; Dunn SR
    Am J Physiol Renal Physiol; 2003 Jun; 284(6):F1138-44. PubMed ID: 12736165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathophysiology of diabetic nephropathy: involvement of multifaceted signalling mechanism.
    Balakumar P; Arora MK; Reddy J; Anand-Srivastava MB
    J Cardiovasc Pharmacol; 2009 Aug; 54(2):129-38. PubMed ID: 19528810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The low dose combination of fenofibrate and rosiglitazone halts the progression of diabetes-induced experimental nephropathy.
    Arora MK; Reddy K; Balakumar P
    Eur J Pharmacol; 2010 Jun; 636(1-3):137-44. PubMed ID: 20347778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy.
    Nakagawa T; Sato W; Glushakova O; Heinig M; Clarke T; Campbell-Thompson M; Yuzawa Y; Atkinson MA; Johnson RJ; Croker B
    J Am Soc Nephrol; 2007 Feb; 18(2):539-50. PubMed ID: 17202420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inflammation and the pathogenesis of diabetic nephropathy.
    Wada J; Makino H
    Clin Sci (Lond); 2013 Feb; 124(3):139-52. PubMed ID: 23075333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors.
    Sugimoto H; Grahovac G; Zeisberg M; Kalluri R
    Diabetes; 2007 Jul; 56(7):1825-33. PubMed ID: 17456853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is the Hp 2-2 diabetic mouse model a good model to study diabetic nephropathy?
    Nakhoul F; Nakhoul N; Asleh R; Miller-Lotan R; Levy AP
    Diabetes Res Clin Pract; 2013 Jun; 100(3):289-97. PubMed ID: 23490597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of diabetic nephropathy--old buddies and newcomers part 2.
    Nawroth PP; Isermann B
    Exp Clin Endocrinol Diabetes; 2010 Nov; 118(10):667-72. PubMed ID: 20658437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endocannabinoids and the renal proximal tubule: an emerging role in diabetic nephropathy.
    Jenkin KA; Verty AN; McAinch AJ; Hryciw DH
    Int J Biochem Cell Biol; 2012 Nov; 44(11):2028-31. PubMed ID: 22842535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice.
    Lassila M; Jandeleit-Dahm K; Seah KK; Smith CM; Calkin AC; Allen TJ; Cooper ME
    J Am Soc Nephrol; 2005 Feb; 16(2):363-73. PubMed ID: 15625075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mouse models of diabetic nephropathy.
    Breyer MD; Böttinger E; Brosius FC; Coffman TM; Harris RC; Heilig CW; Sharma K;
    J Am Soc Nephrol; 2005 Jan; 16(1):27-45. PubMed ID: 15563560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic contributions of carbonyl stress and megsin in diabetic nephropathy.
    Inagi R; Nangaku M; Miyata T
    Ann N Y Acad Sci; 2005 Jun; 1043():605-8. PubMed ID: 16037283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Murine models of diabetic nephropathy.
    Peters V; Schmitt CP
    Exp Clin Endocrinol Diabetes; 2012 Apr; 120(4):191-3. PubMed ID: 22402945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging drugs for diabetic nephropathy.
    Bruno S; Cattaneo D; Perico N; Remuzzi G
    Expert Opin Emerg Drugs; 2005 Nov; 10(4):747-71. PubMed ID: 16262561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SMP-534 ameliorates progression of glomerular fibrosis and urinary albumin in diabetic db/db mice.
    Sugaru E; Nakagawa T; Ono-Kishino M; Nagamine J; Tokunaga T; Kitoh M; Hume WE; Nagata R; Taiji M
    Am J Physiol Renal Physiol; 2006 Apr; 290(4):F813-20. PubMed ID: 16278277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A model for diabetic nephropathy: advantages of the inducible cAMP early repressor transgenic mouse over the streptozotocin-induced diabetic mouse.
    Inada A; Kanamori H; Arai H; Akashi T; Araki M; Weir GC; Fukatsu A
    J Cell Physiol; 2008 May; 215(2):383-91. PubMed ID: 18270980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Losartan in diabetic nephropathy.
    Perico N; Ruggenenti P; Remuzzi G
    Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):473-83. PubMed ID: 15225108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dilazep hydrochloride, an antiplatelet drug, prevents progression of diabetic nephropathy in Otsuka Long-Evans Tokushima fatty rats.
    Yamagishi S; Koga K; Inagaki Y; Amano S; Okamoto T; Takeuchi M
    Drugs Exp Clin Res; 2002; 28(6):221-7. PubMed ID: 12776575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted therapies in diabetic nephropathy: an update.
    Gupta A; Gupta P; Biyani M
    J Nephrol; 2011; 24(6):686-95. PubMed ID: 22058027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.